Group 1 - The company reported a total operating revenue of 566 million yuan, a decrease of 30.12 million yuan compared to the same period last year, representing a year-on-year decline of 5.05% [1] - The net profit attributable to the parent company was 47.38 million yuan, with a net cash inflow from operating activities of 12.26 million yuan [1] Group 2 - The latest debt-to-asset ratio is 28.23%, an increase of 3.94 percentage points from the previous quarter and an increase of 1.53 percentage points from the same period last year [3] - The latest gross profit margin is 83.89%, and the return on equity (ROE) is 2.56% [3] - The diluted earnings per share are 0.28 yuan [3] Group 3 - The total asset turnover ratio is 0.22 times, a decrease of 0.03 times compared to the same period last year, representing a year-on-year decline of 11.46% [3] - The inventory turnover ratio is 0.60 times, a decrease of 0.15 times compared to the same period last year, representing a year-on-year decline of 20.49% [3] Group 4 - The number of shareholders is 9,948, with the top ten shareholders holding a total of 56.37 million shares, accounting for 32.97% of the total share capital [3] - The top ten shareholders and their respective holdings are detailed in the report, with the largest shareholder being Beijing Song'an Investment Management Co., Ltd. holding 22.4 million shares [3]

Group 1 - The company held its sixth board meeting on August 14, 2025, with all seven directors present, and the meeting complied with relevant regulations [5][6]. - The board approved the 2025 semi-annual report and summary, confirming that the report accurately reflects the company's financial status and operational results [6][8]. - The board also approved the special report on the storage and use of raised funds, affirming compliance with regulations and proper management of the funds [9][10]. Group 2 - The company raised a total of RMB 805,890,800.00 from its initial public offering, with a net amount of RMB 725,866,140.61 after deducting issuance costs [13][14]. - As of June 30, 2025, the company had utilized RMB 562,780,017.53 of the raised funds, leaving a balance of RMB 187,562,491.34 [15]. - The company has implemented a cash management plan for temporarily idle raised funds, with a balance of RMB 156,900,000.00 as of June 30, 2025 [21][22]. Group 3 - The supervisory board confirmed that the procedures for compiling and reviewing the semi-annual report were in accordance with legal requirements, ensuring the report's accuracy and completeness [27][28]. - The supervisory board also approved the special report on the storage and use of raised funds, affirming that the company adhered to regulations and did not misuse the funds [29][30]. - The supervisory board evaluated the semi-annual assessment report on the quality improvement and efficiency enhancement action plan, confirming its alignment with the company's strategic goals [31][32].

Group 1 - The board of directors of Beijing Kain Technology Co., Ltd. held its eighth meeting of the sixth session on August 14, 2025, with all seven directors present, ensuring compliance with relevant laws and regulations [1] - The board approved the 2025 semi-annual report and summary, confirming that it accurately reflects the company's financial status, operating results, and cash flow for the first half of 2025 [2] - The board also approved the special report on the storage and use of raised funds for the first half of 2025, affirming compliance with regulatory requirements and confirming no misuse of funds [2][3] Group 2 - The board reviewed and approved the semi-annual evaluation report of the quality improvement and efficiency enhancement action plan for 2025, which aligns with the company's development strategy and reflects the implementation of specific measures [2][3]

证券代码：688687 证券简称：凯因科技 公告编号：2025-027 经审核，监事会认为董事会编制和审核公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 北京凯因科技股份有限公司 第六届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第六届监事会第六次会议 于2025年8月14日以现场结合通讯表决方式在公司会议室召开，会议通知于2025 年8月4日以电子邮件、电话方式送达。会议应出席监事3名，实际出席监事3名。 会议由监事会主席吴垠先生主持。会议的召集、召开符合《公司法》 《公司章程》 和《监事会议事规则》的有关规定。 二、监事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一） 审议通过了《关于公司2025年半年度报告及摘要的议案》 监事会认为：公司编制的《关于 2025 年度提质增效重回报专项行动 ...

证券日报网讯 8月14日晚间，凯因科技发布公告称，公司第六届董事会第八次会议审议通过了《关于公 司2025年度提质增效重回报专项行动方案的半年度评估报告的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Kaiyin Technology announced the approval of several proposals, including the semi-annual evaluation report of the "2025 Quality Improvement and Efficiency Enhancement Return Special Action Plan" by its sixth supervisory board's sixth meeting [2] Group 2 - The announcement indicates a focus on enhancing quality and efficiency for the year 2025, suggesting a strategic initiative aimed at improving company performance [2] - The approval of the semi-annual evaluation report reflects the company's commitment to transparency and accountability in its operational strategies [2] - The meeting's outcomes may signal potential future developments or changes in the company's operational framework, which could impact its market position [2]

Core Insights - The company reported a revenue of 566 million yuan for the first half of 2025, a year-on-year decrease of 5.05%, while achieving a net profit attributable to shareholders of 47.38 million yuan, an increase of 11.75% year-on-year [1] - Despite challenges in the biopharmaceutical industry, the company maintained strategic focus and strengthened its core competitiveness, leading to stable growth in net profit and consolidation of market position [1] Group 1 - The company has optimized its market strategy for the hepatitis C market, collaborating with liver disease experts and targeting grassroots markets to enhance its market presence [1] - The market performance of its product, Kailywei, showed strong resilience during the reporting period, laying a solid foundation for future development [1] Group 2 - The company continues to maintain a leading market position for its mature products, with significant market share for Jinshuxi and Kailyin in their respective segments [2] - The construction of the antibody production base in Beijing has completed the main structure acceptance, with ongoing efficient progress in workshop purification and equipment testing [2] - The company plans to focus long-term on the field of viral and immune diseases, aiming to enhance clinical cure rates through continuous upgrades and iterations of treatment solutions [2]

凯因科技2025半年报 ...

凯因科技（SH 688687，收盘价：36.43元）8月14日晚间发布半年度业绩报告称，2025年上半年营业收 入约5.66亿元，同比减少5.05%；归属于上市公司股东的净利润约4738万元，同比增加11.75%；基本每 股收益0.28元，同比增加12%。 （文章来源：每日经济新闻） ...

证券代码：688687 证券简称：凯因科技 公告编号：2025-027 北京凯因科技股份有限公司 第六届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京凯因科技股份有限公司（以下简称"公司"）第六届监事会第六次会议 于2025年8月14日以现场结合通讯表决方式在公司会议室召开，会议通知于2025 年8月4日以电子邮件、电话方式送达。会议应出席监事3名，实际出席监事3名。 会议由监事会主席吴垠先生主持。会议的召集、召开符合《公司法》《公司章程》 和《监事会议事规则》的有关规定。 二、监事会会议审议情况 会议以投票表决方式审议并通过了如下决议： （一） 审议通过了《关于公司2025年半年度报告及摘要的议案》 经审核，监事会认为董事会编制和审核公司 2025 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容详见公司登载于上海证券交易所网站（www.sse.com.c ...